Publikationen von Staib, Peter

Heudobler, Daniel, Schulz, Christian , Fischer, Jürgen R., Staib, Peter, Wehler, Thomas, Südhoff, Thomas, Schichtl, Thomas, Wilke, Jochen, Hahn, Joachim, Lüke, Florian, Vogelhuber, Martin, Klobuch, Sebastian, Pukrop, Tobias , Herr, Wolfgang, Held, Swantje, Beckers, Kristine, Bouche, Gauthier und Reichle, Albrecht (2021) A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers in Pharmacology 12 (599598), S. 1-10.

Braess, Jan, Amler, Susanne, Kreuzer, Karl-Anton, Spiekermann, Karsten, Lindemann, Hans Walter, Lengfelder, Eva, Graeven, Ullrich, Staib, Peter, Ludwig, Wolf-Dieter, Biersack, Harald, Ko, Yon-Dschun, Uppenkamp, Michael J., De Wit, Maike, Korsten, Stefan, Peceny, Rudolf, Gaska, Tobias, Schiel, Xaver, Behringer, Dirk M., Kiehl, Michael G., Zinngrebe, Bettina, Meckenstock, Gerald, Roemer, Eva, Medgenberg, Dirk, Spaeth-Schwalbe, Ernst, Massenkeil, Gero, Hindahl, Heidrun, Schwerdtfeger, Rainer, Trenn, Guido, Sauerland, Cristina, Koch, Raphael, Lablans, Martin, Faldum, Andreas, Görlich, Dennis, Bohlander, Stefan K., Schneider, Stephanie, Dufour, Annika, Buske, Christian, Fiegl, Michael, Subklewe, Marion, Braess, Birgit, Unterhalt, Michael, Baumgartner, Anja, Wörmann, Bernhard, Beelen, Dietrich und Hiddemann, Wolfgang (2018) Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study. Leukemia 32 (12), S. 2558-2571. Volltext nicht vorhanden.